PDF factsheet

direct oral anticoagulant (DAO) in venous thrombosis for patients with cancer, clinical trials results

edoxaban versus dalteparin
Hokusai-VTE Cancer, 2017
low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily. Treatment was given for atleast 6 months and up to 12 months.
subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily
patients with cancer who had acute symptomatic or incidental venous thromboembolismopen label
idraparinux versus standard treatment
Van Gogh (subgroup), 2011
once-weekly subcutaneous injection of idraparinux (2.5 mg) for 6 months
standard treatment for three months (8%) or six months (92%)
non-active and active cancer patients with deep venous thrombosis and without pulmonary embolism, included in the Van Gogh DVT clinical trial
Follow-up duration: 6 months
rivaroxaban versus dalteparin
SELECT D, 2018
rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months)
dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6)
patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lowerextremity proximal deep vein thrombosis (DVT)open-design
rivaroxaban versus enoxaparin
EINSTEIN (subgroup), 2014
rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg once daily
(enoxaparin1·0 mg/kg twice daily and warfarin or acenocoumarol; international normalised ratio 2·0–3·0
subgroup analysis of patients with active cancer (either at baseline or diagnosed during the study) who were enrolled in the EINSTEIN-DVT and EINSTEIN-PE trials
ximelagatran versus placebo
Schulman (subgroup), 2003
extended treatment with Ximelagatran 24mg twice daily after initial anticoagulant treatment for 6 months
placebo (initial anticoagulant treatment for 6 months)
study subgroup of patients with active cancer in the previous 5 years treated for DVT or pulmonary embolism for 6 months without recurrencesingle blind and outcome ass.
Follow-up duration: 18 months


in first

in second